

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Llinas-Brunet, M. et al

Appln. No. 09/368,670

Group Art Unit: 1653

Filed: 08/05/1999

Examiner: D. Lukton

For: Hepatitis C Inhibitor Peptides

Atty. Docket No. 13/063-2-C2

STATEMENT UNDER 37 CFR § 1.821(f)

Assistant Commissioner For Patents
Washington, D.C. 20231


Sir:

I hereby certify that:

The new paper Sequence Listing and new computer readable form (CRF)

Sequence Listing submitted herewith are identical.

Respectfully submitted,




Philip I. Datlow
Attorney for Applicant(s)
Reg. No. 41,482

Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on May 31, 2001



By: Philip I. Datlow
Reg. No. 41,482